• Home
• Media centre
• Press release archive

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Regulatory update for REZONIC™ (casopitant mesylate)

GlaxoSmithKline (NYSE: GSK) confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant. 

The company is reviewing this letter and will engage with the FDA to determine appropriate next steps.

A complete response letter is issued by FDA’s Center for Drug Evaluation and Research (CDER) when the review of a file is completed and questions remain that preclude the approval of the application. 

Casopitant was originally filed with the FDA on 29 May 2008, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). 

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

 

	GlaxoSmithKline Enquiries:
	UK Media enquiries:	Philip Thomson	(020) 8047 5502
		David Outhwaite	(020) 8047 5502
		Stephen Rea	(020) 8047 5502
	US Media enquiries:	Lisa Behrens	(919) 483 2839
		Ken Inchausti	(919) 483 2839
	European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
		Sally Ferguson	(020) 8047 5543
		Gary Davies	(020) 8047 5503
	US Analyst/ Investor enquiries:	Tom Curry	(215) 751 5419
		Jen Hill Baxter	(215) 751 7002
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS